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Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) is currently the eighth leading cause of cancer death
worldwide. The often severe side effects, functional impairments and unfavorable cosmetic outcome of conventional
therapies for HNSCC have prompted the quest for novel treatment strategies, including the evaluation of
nanotechnology to improve e.g. drug delivery and cancer imaging. Although silica nanoparticles hold great promise for
biomedical applications, they have not yet been investigated in the context of HNSCC. In the present in-vitro study we
thus analyzed the cytotoxicity, uptake and intracellular fate of 200-300 nm core-shell silica nanoparticles encapsulating
fluorescent dye tris(bipyridine)ruthenium(II) dichloride with hydroxyl-, aminopropyl- or PEGylated surface modifications
(Ru@SiO2-OH, Ru@SiO2-NH2, Ru@SiO2-PEG) in the human HNSCC cell line UMB-SCC 745.
Results: We found that at concentrations of 0.125 mg/ml, none of the nanoparticles used had a statistically
significant effect on proliferation rates of UMB-SCC 745. Confocal and transmission electron microscopy showed an
intracellular appearance of Ru@SiO2-OH and Ru@SiO2-NH2 within 30 min. They were internalized both as single
nanoparticles (presumably via clathrin-coated pits) or in clusters and always localized to cytoplasmic membrane-
bounded vesicles. Immunocytochemical co-localization studies indicated that only a fraction of these nanoparticles
were transferred to early endosomes, while the majority accumulated in large organelles. Ru@SiO2-OH and
Ru@SiO2-NH2 nanoparticles had never been observed to traffic to the lysosomal compartment and were rather
propagated at cell division. Intracellular persistence of Ru@SiO2-OH and Ru@SiO2-NH2 was thus traceable over 5 cell
passages, but did not result in apparent changes in cell morphology and vitality. In contrast to Ru@SiO2-OH and
Ru@SiO2-NH2 uptake of Ru@SiO2-PEG was minimal even after 24 h.
Conclusions: Our study is the first to provide evidence that silica-based nanoparticles may serve as useful tools for
the development of novel treatment options in HNSCC. Their long intracellular persistence could be of advantage
for e.g. chronic therapeutic modalities. However, their complex endocytotic pathways require further investigations.
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1. Introduction
Head and neck squamous cell carcinoma (HNSCC)
comprise a group of epithelial cancers that arise from e.
g. the lips, the oral or nasal cavity, salivary glands, para-
nasal sinuses, pharynx or larynx [1]. With a worldwide
incidence of more than 600’000 new cases per year,
HNSCC accounts for about 6% of all malignant diseases
diagnosed (http://globocan.iarc.fr). If detected early,
patients have cure rates of about 90%. However, 60% of
patients present with advanced disease or loco-regional
lymph node metastasis at the time of diagnosis and have
a poor prognosis [2,3].
Currently, treatment options for HNSCC patients
include surgery, radiotherapy, chemotherapy or a combi-
nation of them [4,5]. Due to the distinct localization of
these tumors in regions with anatomic structures
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important to e.g. breathing, mastication, swallowing or
phonation, invasive treatment regimes frequently leading
to severe functional impairments - often accompanied
by unfavorable cosmetic outcomes. This is true despite
significant advancements made in the reconstructive
abilities over past two decades. Moreover, radiation may
have long-term effects on surrounding healthy struc-
tures such as parts of the brain, the spinal cord or sali-
vary glands. However, while surgery or radiation therapy
is local, chemotherapy is applied systemically and may
thus result in severe adverse effects e.g. on blood cell
production (anaemia, neutropenia, thrombopenia), the
mucosa (mucositis), the auditory and vestibular system
(ototoxicity) or the kidneys (nephrotoxicity). Despite
this aggressive therapeutic regime, to date many patients
with advanced disease cannot be cured and more then
half of them die within five years [6-8]. HNSCC is thus
currently the eighth leading cause of cancer death
worldwide.
To overcome at least some of the challenges in the
therapy of patients with advanced HNSCC, the applica-
tion of nanoparticles has been evaluated with regard to
their advantages for chemotherapeutic/medicinal, radia-
tion and imaging strategies. Previous data indicates that
cytotoxic drugs such as mitoxantron, cisplatin or pacli-
taxel as well as the photosensitizer 5,10,15,20-tetrakis
(meso-hydroxyphenyl)porphyrin (mTHPP) encapsulated
in superparamagnetic, liposome, albumin or methoxy
poly(ethylene glycol)-poly(lactide-co-glycolide) (MPEG-
PLGA) nanoparticles or polymeric micelles not only
exhibit potent antitumor activity, but also displayed
reduced side effects [9-13]. Furthermore, it has been
reported that beta-emitting radionuclides attached to
liposomes showed promising results when applied intra-
tumorally and gold nanoparticles or nanoparticles with
antisense oligonucleotides against the gene ataxia-telan-
giectasia-mutated (ATM) improved radiosensitivity in
rodent head and neck cancer models [14-16]. In addi-
tion, superior imaging in head and neck cancers resulted
from the use of superparamagnetic iron oxide nanopar-
ticles, gold nanoparticles or gadolinium-labelled phos-
phorescent polymeric nanomicelles [17-22].
In the past years, silica-based nanoparticles have
gained increasing interest for medical applications
because of their biocompatibility, versatility and stability.
Numerous in-vitro and in-vivo studies pointed towards
their great potential for improving the efficacy of thera-
peutic agents in tumor cells by e.g. circumventing solu-
bility and stability problems of certain drugs or enabling
targeted delivery and controlled release strategies
[23-25]. Moreover, silica nanomaterials have been pro-
posed as promising medical tools for biosensing [26,27]
and imaging purposes [28].
However, to our knowledge, silica nanoparticles have
not yet been investigated in the context of head and
neck cancers. In this work, we assess the biological in-
vitro behaviour of core-shell silica based nanoparticles
on the HNSCC cell line UMB-SCC-745 with regard to
their cytotoxicity, uptake, localization and intracellular
fate.
2. Materials and methods
2.1. Synthesis of nanoparticles
Spherical core-shell silica nanoparticles encapsulating
tris(bipyridine)ruthenium(II) dichloride [Ru(bpy)3]Cl2 as
fluorescent dye were produced as described before [29].
The method is based on an oil-in-water microemulsion
of n-hexanol-TritonX100-cyclohexane, [Ru(bpy)3]Cl2,
tetraethyl-orthosilicate (TEOS) and ammonia. The sur-
face chemistry of mono-shell silica nanoparticles was
modified by the addition of a mixture of TEOS and
other organosilanes, such as 3-aminopropyltriethoxysi-
lane (APTES) to generate aminopropyl and hydroxyl
functionalities (Ru@SiO2-NH2 and Ru@SiO2-OH) at the
nanoparticle surface. Similarly, PEGylated [Ru(bpy)3]Cl2-
labeled dual-shell nanoparticles (Ru@SiO2-PEG) have
been synthesized as previously described, using a mix-
ture of TEOS and bis(silylated)polyethylene glycol
(SPEGS) for growth of a PEGylated second shell [30].
All the three types of nanoparticles have been fully char-
acterized, as precedently described and have an average
size ranging between 200 and 300 nm [30]. The surface
charge and the hydrophilic character of nanoparticles
have been explored based on their electrophoretic mobi-
lity in nanopure water at neutral pH (Zetasizer Nano
ZS, Malvern Instruments Ltd., UK).
2.2. Cell Culture
The head and neck squamous carcinoma cell line UMB-
SCC-745 was kindly provided by Dr. Robert Mandić,
Department of Otolaryngology, Philips University, Mar-
burg, Germany. The UMB-SCC-745 was derived from
the tonsil tumor of a 48-year-old man and has a distinct
p53 single point mutation and loss of heterozygosity [31].
Monolayer
UMB-SCC-745 cells were cultured under standard con-
ditions (37°C, 5% CO2, 95% air atmosphere) in growth
medium, i.e. RPMI Medium (Invitrogen, Basel, Switzer-
land) supplemented with 10% fetal calf serum (FCS,
Sigma-Aldrich, Buchs, Switzerland), 1% HEPES (Invitro-
gen), 1% MEM non essential amino acids (Invitrogen)
and 1% penicillin and streptomycin (Invitrogen). The
growth medium was changed every second day. The
passage of the cells was performed by trypsination (tryp-
sin 1×, Invitrogen) when reaching confluence, in general
every 2-3 days.
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Multicellular spheroids (3D cell culture)
For generation of multicellular spheroids, we applied a
modified hanging drop method [32]. Briefly, 96-well
plates were coated with 60 μl of 1.5% agarose (Sigma-
Aldrich) per well, in RPMI medium without FCS. Then
20 μl drops of UMB-SCC 745 cell solution (5000 cells/
20 μl) were placed on the plate lid, the lid was posi-
tioned back to the plate and then kept overnight in the
incubator (37°C, 5% CO2). The following day, 80 μl
growth medium was added to the wells, the plates were
shortly centrifuged and returned to the incubator. In
order to avoid vibration, which has an influence on the
formation of spheroids, the incubator should not be
opened for the first 48 hours. After this initial time
spheroids were stable in their form and reached the
desired diameter of 150 μm two days later.
2.3. Proliferation assay
The cytotoxicity of nanoparticles was evaluated using a
commercial cell proliferation assay (Cell Proliferation
ELISA, BrdU, chemiluminescent, Roche, Basel, Switzer-
land). For this experiment the cells were cultured in
black Greiner-96-well plates (2000 cells/well, Cellstar,
Frickenhausen, Germany) with 100 μl growth medium
at 37°C, 5% CO2 for 24 h. Subsequently the growth
medium was replaced with fresh one containing
Ru@SiO2-OH, Ru@SiO2-NH2 or Ru@SiO2-PEG nano-
particles at final concentrations ranging between 0.03
mg/ml - 0.5 mg/ml. Nanoparticles were ultrasonicated
for 2 h before incubation to ensure their homogeneity.
After nanoparticle incubation for 5 h, the cells were
washed with phosphate buffered saline (PBS, Oxoid,
Hampshire, United Kingdom) and incubated overnight
with fresh growth medium containing BrdU-labeling
agent. BrdU, which is incorporated only in viable cells
during DNA synthesis, was detected with an ELISA
immunoassay according to the recommendation of the
manufacturer. The resulting signal was quantified by
measuring the photons using a micro-plate luminometer
with photomultiplier technology (BioTek, Luzern, Swit-
zerland). The relative light units/second (rlu/s) directly
correlates to the amount of DNA synthesis and hereby
to the number of proliferating cells in the respective
microcultures.
2.4. Exposure protocols of nanoparticles
For all experiments, nanoparticles were ultrasonicated
for 2 h directly prior to use in cell culture.
For the uptake study the cells were seeded either on
six-well plates (1’000’000 cells/well) for transmission
electron microscopy (TEM) or on poly-L-lysine (PLL,
0.25 mg/ml, Sigma-Aldrich) -coated glass cover slips
(50’000 cells, Hecht-Assistant, Sondheim, Germany) for
confocal laser scanning microscopy (CLSM). The cells
were then incubated with either Ru@SiO2-OH,
Ru@SiO2-NH2 or Ru@SiO2-PEG nanoparticles (final
concentrations 0.125 mg/ml) for different time periods
(30 min, 1 h, 2 h, 5 h, 7 h, 12 h and 24 h) under cell
culture conditions. After each time point cell aliquots
were used for microscopic monitoring by CLSM and
TEM.
Alternatively, multicellular spheroids were grown for 4
days in 96-well plates and also exposed to Ru@SiO2-OH
and Ru@SiO2-NH2 nanoparticles for 5 h and 24 h,
respectively, at final concentrations of 0.125 mg/ml
under cell culture conditions. The nanoparticle distribu-
tion in spheroids was monitored only by CLSM.
For long-time experiments, cells were grown in six-
well culture plates and incubated under cell culture con-
ditions with Ru@SiO2-OH and Ru@SiO2-NH2 nanopar-
ticles for 5 h (final concentrations 0.125 mg/ml).
Following an extensive washing step with PBS, cells
were directly passaged, re-seeded (500’000 cells/well) in
cell culture plates and kept in culture until confluence
(three days). The growth medium was exchanged every
day. Passaging of the cells was continued until fifth pas-
sage. After each passage aliquots of the cells were used
for evaluation by both CLSM and TEM.
For control experiments, cells or spheroids were cul-
tured as above, but nanoparticle-containing medium
was replaced by growth medium.
Protocols for CLSM (TCS-SP2 and TCS-SP5, Leica,
Heerbrugg, Switzerland): After exposure to nanoparti-
cles and washing steps, cells on cover slips were fixed
for 15 min with PBS containing 1% paraformaldehyde
(PFA, Sigma-Aldrich) and 0.33% saccharose (Sigma-
Aldrich). Visualisation of nuclei were performed by
incubation with 4’-6-diamidion-2-phenylindole (DAPI, 1
μg/ml, Roche) and mounted with GlycerGel mounting
medium (Dako, Baar, Switzerland).
In experiments concerning multicellular spheroids,
nuclei were stained with Hoechst staining dye (1 μg/ml,
Sigma-Aldrich), which was added for the last hour of
incubation. After incubation, the spheroids were col-
lected, washed with PBS, fixed with PBS containing 1%
PFA for 30 minutes, washed again with PBS and then
monitored by confocal microscopy.
[Ru(byp)3]
2+ complexes were excited with a 458 nm
laser and detected in the range of 570 - 650 nm. Visuali-
sation of nuclei (DAPI and Hoechst staining) was
achieved with an excitation wavelength of 350 nm and a
detection wavelength range of 450 - 500 nm.
Protocols for TEM (CM100, TEM, Philips, Guildford,
UK): After nanoparticle incubation and washing steps
cells were fixed with 2.5% glutaraldehyde (GA, Electron
Microscopy Sciences, Hatfield, USA) and 0.8% PFA in
0.05 M dimethylarsenic acid sodium salt trihydrate (Na-
Caco, Merck, Darmstadt, Germany) buffer at 1:9 ratio
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for 30 minutes. The samples were washed once with
0.05 M Na-Caco buffer and then fixed for 1 h with 2%
osmium-tetra-oxide and 3% potassium hexacyano-ferrate
(II) trihydrate (Sigma-Aldrich) at 1:1 ratio. After wash-
ing and centrifugation, cell pellets were transferred to
2.5% bacto agar (Agar Scinetific, Wetzlar, Germany),
dehydrated in 70-100% ethanol and embedded in
embedding medium (Glycidether 100 (Promega); dode-
cenylsuccinic-anhydride (Sigma-Aldrich); nadic methyl
anhydride (Sigma-Aldrich) and N, N-dimethylbenzyla-
min purum (Sigma-Aldrich) as activator) for 24 h at 80°
C. Sections (70 nm) were contrasted with uranyl acetate
dihydrate (Sigma-Aldrich) and lead (II) citrate (Sigma-
Aldrich) for 20 minutes each.
2.5. Immunocytochemistry
UMB-SCC-745 cells cultured on PLL coated cover slides
were incubated for 5 hours with Ru@SiO2-PEG,
Ru@SiO2-OH and Ru@SiO2-NH2 nanoparticles at final
concentrations of 0.125 mg/ml. After incubation cells
were fixed for 15 min with 1% PFA in PBS, permeabi-
lized with 0.01% Triton-X 100 (Roche) for 1.5 min,
blocked for 30 min at room temperature with 0.1%
bovine serum albumine (BSA, Calbiochem, San Diego,
USA) and washed with PBS. For labelling of early endo-
somes, rabbit anti-EEA1 antibody (1:300, stock concen-
tration 1.3 mg/ml, Sigma-Aldrich) was used. Rabbit
anti-Rab7 antibody (1:300, stock concentration 1.2 mg/
ml, Sigma-Aldrich) was used to visualize late endosomes
and for labelling of Golgi apparatus mouse anti-GM130
antibody (1:500, stock concentration 0.7 mg/ml, Abcam,
Cambridge, UK) was used. Cells were incubated with
primary antibodies for 2 h at room temperature or over-
night at 4°C, washed and incubated with FITC-labelled
donkey anti-rabbit or anti-mouse antibodies, respectively
(both 1:500, Sigma-Aldrich), together with DAPI (1 μg/
ml) for 1 h at room temperature. Lysosomes and mito-
chondria were visualized with Lysotracker Red and
Mitotracker Orange respectively (working concentration
for both 300 nM, Invitrogen). For examination by
CLSM (Leica), [Ru(byp)3]
2+ complexes and nuclei have
been detected as described above, while for FITC excita-
tion and detection wavelengths of 488 nm and 490-540
nm, respectively, have been used.
3. Results
Electrophoretic mobility of Ru@SiO2-OH particles
revealed a ζ-potential of -40 mV, which is in good
agree, ζ-potentials of +11.3 mV and +4.29 mV have
been obtained, respectively. As a prerequisite for our
studies we first determined optimal concentrations of
the different surface-modified nanoparticles in our in-
vitro model (Figure 1). BrdU proliferation assays indi-
cated for all types of nanoparticles that concentrations
ranging between 0.03 - 0.125 mg/ml had no statistic-
ment with the values measured for bare (non doped)
SiO2 nanoparticles, whereas in the case of amino- and
PEG-modified particlesally significant effect on cell pro-
liferation compared to untreated controls. Ru@SiO2-
PEG had no impact on cell growth even at higher con-
centrations (0.25 - 0.5 mg/ml). However, 0.25 and 0.5
mg/ml of Ru@SiO2-NH2 nanoparticles negatively
affected proliferation rates, leading to an average of 21%
and 31% reduced incorporation of BrdU, respectively.
Ru@SiO2-OH nanoparticles diminished cell proliferation
up to 41% at highest nanoparticle concentrations (0.5
mg/ml), while a reduction below 10% was observed at
0.25 mg/ml. Based on these results we decided to use
concentrations of 0.125 mg/ml for all three Ru@SiO2
nanoparticles for further experiments.
To obtain information about the cellular uptake of
Ru@SiO2-PEG, Ru@SiO2-OH and Ru@SiO2-NH2 we
conducted electron microscopic studies in UMB-SCC
745 cells. Generally, nanoparticle incubation did not
result in an obvious ultrastructural damage compared to
untreated controls. Both Ru@SiO2-OH and Ru@SiO2-
NH2 were detected intracellularly already 30 min after
nanoparticle incubation. In case of single nanoparticles,
internalization involved invaginations of the plasma
membrane that are lined by electron dense material at
the cytoplasmic side. Furthermore, clusters of nanoparti-
cles were internalized by membrane ruffling (Figure 2).
In all cases, nanoparticles were found in membrane-
bounded vesicles within the cytoplasm. Intracellular
amounts of Ru@SiO2-OH and Ru@SiO2-NH2 nanoparti-
cles steadily increased between 30 min and 5 h post
incubation (Figure 3 and 4). However after 24 h, large
vesicles with many nanoparticles were found in favour
of vesicles with single nanoparticles (Figure 5). Despite
multiple washing steps during sample preparation for
TEM, considerable amounts of nanoparticles were
attached to the cell surface at all time points
investigated.
In contrast to the other studied nanoparticles, the
uptake of Ru@SiO2-PEG into UMB-SCC 745 cells was
minimal (Figure 6). Very few Ru@SiO2-PEG nanoparti-
cles were observed after 5 h of incubation and then only
in a minority of cells. Neither an increase in uptake over
time nor an affinity to the outer cell membrane as with
the other nanoparticles could be observed. These data
lead us to exclude Ru@SiO2-PEG from further
experiments.
The uptake of Ru@SiO2-OH and Ru@SiO2-NH2
nanoparticles had been additionally investigated in a 3D
cell culture system (Figure 7). Confocal microscopy
revealed that an intense [Ru(bpy)3]Cl2 fluorescence was
visible after 5 h in the cytoplasm of cells constituting
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the outer layer of spheroids while inner cells were
devoid of such signals.
With the aim to better characterize the intracellular
fate of nanoparticles, immunohistochemical studies with
antibodies against markers of endocytotic pathways were
performed. CLSM analyses showed that at all time
points investigated immunoreactions for Rab7, GP 120,
Mitotracker and Lysotracker were present, but never co-
localized with Ru@SiO2-OH or Ru@SiO2-NH2 nanopar-
ticles. In contrast, a subfraction of EEA1 immunosignals
coexisted with Ru@SiO2-OH and Ru@SiO2-NH2 fluor-
escence after 2 h of incubation, reaching a maximum at
5 h (Figure 8). This observation was slightly more pro-
nounced in Ru@SiO2-OH. However, the majority of [Ru
(bpy)3]Cl2 fluorescent nanoparticles was not located
together with EEA1 immunoreactivity. Co-localization
with EEA1 after 24 h of incubation was negligibly low
for both nanoparticle types, even if it was slightly higher
for Ru@SiO2-OH.
In addition, we investigated the presence of
Ru@SiO2-OH or Ru@SiO2-NH2 nanoparticles over a
time span of 15 days (i.e. over five cell passages) in
UMB-SCC 745 cells (Figure 9). During the whole
experiment no signs of degradation of Ru@SiO2 nano-
particles could be observed. During the first two days
after Ru@SiO2-OH or Ru@SiO2-NH2 incubation all
cells contained large numbers of nanoparticles. How-
ever, at day four, Ru@SiO2-OH nanoparticles were
detected only in about 50% of cells, while Ru@SiO2-
NH2 nanoparticles were still present in more than 70%
of the cell population. Nine days after incubation,
Ru@SiO2-OH and Ru@SiO2-NH2 nanoparticles were
visible in less then 30% and about 50% of all cells,
respectively. Generally, we found that during mitosis
nanoparticles were either only propagated to one
daughter cell or distributed between both daughter
cells (Figure 10). At day 12 all cells exhibited a cyto-
plasm free of Ru@SiO2-OH. In contrast, Ru@SiO2-
NH2 nanoparticles were found up to day 15, however,
the detectable amounts were low.
4. Discussion
The large data corpus of recent years provides evidence
that silica nanomaterials may have the potential to
strongly improve cancer treatment and diagnosis. Silica
nanomaterials feature the versatility necessary for
tumor-specific modifications, stability in the often harsh
environments of the body, ease of production and -
more importantly - they are generally regarded as bio-
compatible. However, the latter clearly depends on
many parameters such as particle size, surface modifica-
tion, dose, exposure time or cell type used as model
[33]. With the aim to explore the suitability of silica
nanoparticles for new concepts in the treatment of head
and neck cancers we investigated as a first step the bio-
logical in-vitro behaviour of non-targeted 200-300 nm
core-shell silica nanoparticles with three different sur-
face modifications.
Figure 1 Proliferation effects of different surface modified nanoparticles on UMB-SCC 745. BrdU proliferation assays in UMB-SCC 745 cells
after incubation (5 h) of nanoparticles with different surface modifications (Ru@SiO2-OH, Ru@SiO2-NH2 and Ru@SiO2-PEG) at concentration
ranges of 0-0.5 mg/ml.
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While both Ru@SiO2-OH and Ru@SiO2-NH2 nano-
particles displayed high uptake rates in our model, inter-
nalization of PEGylated silica nanoparticles was almost
completely lacking under the same experimental condi-
tions. Although we observed this effect in the related
HNSCC line UMB-SCC 969 and in the human prostate
carcinoma cell line PC-3 as well (unpublished data),
other studies showed, in contrast to our results, that
PEGylated silica nanoshells are at least able to attach to
the outside of MCF-7 cells [34]. However, PEG is
known for its cell-repelling properties [35-37], but
uptake efficiency may be increased by the addition of
targeting ligands [38]. Since grafting of nanoparticles
with PEG has been reported to be advantageous for in-
vivo applications - basically due to its increased half-live
in circulation - and helpful for targeting, the generation
of optimized Ru@SiO2-PEG may be worthwhile (work
in preparation).
Although the plasma membrane is negatively charged,
the different surface charges of (negatively charged)
Ru@SiO2-OH and (positively charged) Ru@SiO2-NH2
nanoparticles had no considerable influence on cellular
uptake kinetics in our model. This is in contrast to
reports indicating that negatively charged nanomaterials
are less effectively internalized [39]. However, a large
number of studies show that both cationic and anionic
nanoparticles are capable of effectively passing the cell
membrane [39].
Our data indicates that at nanoparticle concentrations
of 0.125 mg/ml and below, no perturbances in cell cycle
progression have been detected under our experimental
conditions. An increase of cancer cell proliferation could
be dangerous and hold dire consequences in clinical set-
tings. This phenomenon has been reported in-vitro for
melanoma cells and mesoporous silica nanoparticles
[40], but has never been observed in our experiments.
Figure 2 Nanoparticle internalisation. Transmission electron microscopy pictures of nanoparticle internalisation in UMB-SCC 745 exemplarily
shown for Ru@SiO2-NH2. Uptake occurred either as single nanoparticle (A, B, scale bars = 100 nm), or nanoparticle clusters (C, D, scale bars =
500 nm).
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However, higher concentrations of Ru@SiO2-OH and
Ru@SiO2-NH2 lead to reduced proliferation rates. While
a slowdown in growth of tumor cells may be generally
regarded as a positive effect in cancer treatment it
should be emphasized that the underlying pathomechan-
isms in HNSCC are not clear yet. Previous in-vitro stu-
dies in other cancer cell lines have shown that
cytotoxicity of silica nanoparticles, in relation to size
and incubation time, may be due to oxidative stress
with lipid peroxidation and membrane damage and/or
an inflammatory response [41,42]. A detailed analysis of
the complex molecular pathways involved is therefore
needed in order to estimate possible (wanted or
unwanted) consequences for future therapeutic strate-
gies. Because of the different experimental design (e.g.
longer incubation times, different particle sizes, other
cell lines) it is impossible to directly compare our cyto-
toxicity data with previous studies. However, head and
neck cancer cells seem to display cell toxic effects at
concentrations comparable to other cancer cells, e.g.
cervical adenocarcinoma cells [43], osteosarcoma cells
[42], lung adenocarcinoma cells [37,41], and gastric and
colon cancer cells [44]. Despite this, nanoparticle con-
centrations have to be carefully adjusted: using the same
nanoparticles and experimental conditions as here, PC-3
human prostate cancer cells displayed a proliferation
stagnation of about 15 days after nanoparticle incuba-
tion, although metabolic rates have been found to be
higher (Besic Gyenge et al., unpublished).
With regard to internalization processes of nanoparti-
cles into cells, phagocytosis, pinocytosis and caveolin- or
clathrin-driven endocytosis have all been proposed and
seem to strongly depend on particle form, size and cell
type used. With our experimental set-up, apparently two
different routes of nanoparticle uptake occur in parallel:
on the one hand, single particles enter HNSCC cells via
Figure 3 Time dependent uptake of Ru@SiO2-OH nanoparticles. Ru@SiO2-OH nanoparticle uptake over 2 h (A and B) and 24 h (C and D) in
UMB- SCC 745. A, C: confocal laser scanning microscopy, showing nuclei in blue and Ru@SiO2-OH nanoparticles in red, scale bars = 20 μm. B, D:
transmission electron microscopy, scale bars = 10 μm.
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Figure 4 Time dependent uptake of Ru@SiO2-NH2 nanoparticles. Ru@SiO2-NH2 nanoparticles uptake over 2 h (A and B) and 24 h (C and D)
in UMB-SCC 745. A, C: confocal laser scanning microscopy, showing nuclei in blue and Ru@SiO2-NH2 nanoparticles in red, scale bars = 20 μm. B,
D: transmission electron microscopy, scale bars = 10 μm.
Figure 5 Intracellular localisation of Ru@SiO2-OH and Ru@SiO2-NH2 nanoparticles after 24 h. Transmission electron microscopy showing
intracellular localisation of nanoparticles in UMB-SCC 745 after 24 h of incubation. A) Ru@SiO2-NH2 nanoparticles and B) Ru@SiO2-OH
nanoparticles. Scale bars = 5 μm.
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membrane invaginations that ultrastructurally resemble
clathrin-coated pits. The involvement of clathrin-coated
pits in internalization mechanisms of silica nanoparticles
had also been proposed in several previous in-vitro stu-
dies using specific inhibitors or confocal methods
[45-48]. On the other hand, the observed bulk internali-
zation of nanoparticles is likely related to non-clathrin
mediated endocytosis. The latter process rather displays
features of macropinocytosis, such as membrane ruf-
fling. Notably, the different surface charges of our nano-
particles did not play an apparent role with regard to
the observed uptake mechanisms. Detailed studies are
now needed to further characterize the events taking
place at the plasma membrane upon contact with our
silica nanoparticles. However, the incidence of such dif-
ferent simultaneous endocytosis modes of silica nano-
particles is in accordance with a recent paper, where
also discrete entry pathways have been observed for
single and agglomerated amorphous silica nanoparticles
[48]. Furthermore, in mouse melanoma cells, internali-
zation of latex particles of 200 nm (that corresponds
approx. to the size of our particles) involved clathrin-
coated pits, while latex particles of 500 nm (that corre-
sponds approx. to our nanoparticle clusters) preferen-
tially entered the cells via a clathrin-independent
caveolin-associated pathway [49].
To characterize the intracellular fate of our silica
nanoparticles within HNSCC, we next investigated their
possible delivery into early and late endosomes and lyso-
somes. The localization of Ru@SiO2-OH and Ru@SiO2-
NH2 in early endosomes indicates their processing to
endocytotic pathways, however, a considerable number
of particles obviously used a different route of traffick-
ing, that did not involve EEA1-positive organelles. As
long as these organelles have not been characterized, a
possible role of nanoparticle’s surface charge for
Figure 6 Time dependent uptake of Ru@SiO2-PEG nanoparticles. Ru@SiO2-PEG nanoparticle uptake after 2 h (A and B) and 24 h (C and D)
in UMB-SCC 745. A, C: confocal laser scanning microscopy, showing nuclei in blue and Ru@SiO2-PEG nanoparticles in red, scale bars = 20 μm. B,
D: transmission electron microscopy, scale bars = 10 μm.
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endocytic processes cannot be defined. However, the
acidic pH of early endosomes may explain the slightly
higher frequency of (negatively charged) Ru@SiO2-OH
in EEA1-containing vesicles.
While we cannot exclude that some Ru@SiO2-OH and
Ru@SiO2-NH2 may have been shuttled back to the
plasma membrane for segregation, the majority of nano-
particles remained intracellularly and accumulated in
rather large vesicles 24 h after incubation. We propose
that the latter is related to homotypic vesicle fusion. No
transfer to Golgi apparatus-related pathways has been
detected. More importantly, we found that nanoparticle-
bearing vesicles did neither mature from early endo-
somes into (Rab7-positive) late endosomes nor locate to
lysosomes. While both the known stability of silica-shell
nanoparticles and possible cancer-related changes in
Figure 7 Ru@SiO2-OH and Ru@SiO2-NH2 nanoparticle uptake in multicellular spheroids. Uptake of nanoparticles in UMB-SCC 745
multicellular spheroids after 5 hours. Confocal laser scanning microscopy pictures, showing Ru@SiO2-OH (A) and Ru@SiO2-NH2 (B) in red and cell
nuclei in blue. Scale bars = 100 μm.
Figure 8 Co-localisation of Ru@SiO2-OH and Ru@SiO2-NH2 nanoparticles with early endosomes. Confocal laser scanning microscopy
pictures showing a partial co-localisation after 2 h of incubation of Ru@SiO2-OH (A, in red) or Ru@SiO2-NH2 (B, in red) fluorescence with
immunosignals for early endosomes protein 1 (A, B, in green). Cell nuclei are stained in blue. Arrows denote large early endosomes, which
contain high amounts of nanoparticles. Scale bars = 30 μm.
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endosomal sorting mechanisms may have prevented
their targeting to degradation pathways, our data is in
contrast to other studies showing that silica nanoparti-
cles are in fact transferred to lysosomes [46,47,50]. Our
results also differ from those of Rejman et al. [49] where
a size-dependency of endocytotic pathways had been
proposed. In this study, at least smaller latex particles
(200 nm) passaged to late endosomes/lysosomes while
only large particles (500 nm) did not [49]. We therefore
conclude that intracellular fate of nanoparticles not only
depends on their size (or agglomeration status) but pre-
sumably also on cell line.
Although the exact nature of different endocytotic
organelles in our model has to await further
Figure 9 Intracellular long time retention of nanoparticles. Transmission electron microscopy pictures of UMB-SCC 745 after nanoparticle
incubation over a time period of 15 days. A-C) 2, 9 and 12 days after incubation of Ru@SiO2-OH nanoparticles. D-F) 2, 9 and 12 days after
incubation of Ru@SiO2-NH2 nanoparticles. Scale bars for A-E) = 5 μm and for F) = 0.5 μm.
Figure 10 Nanoparticle distribution during cell division. Confocal laser scanning microscopy showing distribution of RuSiO2-NH2
nanoparticles during cell division (third passage) of UMB-SCC 745. A) metaphase and B) telophase, nucleus in blue and nanoparticles in red.
Scale bars = 10 μm.
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characterization, the strictly vesicle-associated occur-
rence of Ru@SiO2-OH and Ru@SiO2-NH2 in HNSCC
may have contributed to their biocompatibility. In
human melanoma cells it had been reported that an
escape of silica nanoparticles to the cytoplasm resulted
in changes of the cytoskeleton as well as of adhesion
and migration properties [51]. Whether the vesicular
enclosure of our nanoparticles is a useful feature in the
case of intracellular drug delivery strategies in HNSCC
remains to be proven.
In addition to their relatively large diameter [52,53],
the absence of free Ru@SiO2-OH and Ru@SiO2-NH2
within the cytoplasm of HNSCC may have been the
reason that nanoparticles never passed the nuclear
membrane. Even though localizations of silica nano-
particles within the nucleus had been observed before
[54], our data is in accordance with results from pre-
vious studies [53,55,56]. Recently, it had been shown
that labeling with fluorophores may affect uptake
kinetics and intracellular pathways of certain probes
[57]. However, due to encapsulation of the dye in our
study, it is unlikely that [Ru(bpy)3]Cl2 may have influ-
enced routes of nanoparticles within cells. Until now,
very little is known about the intracellular long-term
fate of silica nanoparticles and possible consequences
of their persistence in biological systems. In human
lung epithelial cells, Stayton et. al. observed a slow but
active transfer of silica nanoparticles from the cyto-
plasm to the exterior environment [58]. They showed
that during the first 24 h almost 50% of nanoparticles
exited the cells. In contrast, our data implicates that
both internalized Ru@SiO2-OH and Ru@SiO2-NH2
remain within the cell and are apparently distributed
between daughter cells at cell division. During the
course of several passages, initially high nanoparticle
amounts in individual cells become “diluted”, but ultra-
structurally are still found in vesicles. The reason for
the observed differences in long-time persistence of
Ru@SiO2-OH and Ru@SiO2-NH2 are not clear yet, but
may also be related to as yet uncharacterised charge-
dependent effects of nanoparticles on endolysosomal
pathways. However, in addition of not featuring acute
cell toxic effects, the presence of our silica nanoparti-
cles over 15 days caused no visible changes in viability,
proliferation or morphology in HNSCC. Of note, over
the time course studied, ultrastructure of nanoparticles
appears to remain unchanged. However, it cannot be
excluded that discrete processes of nanoparticle degra-
dation occurred. Recently, it had been reported that,
depending on functionalization, integrity of silica nano-
particles may be impaired step-wise over time in simu-
lated body fluid with regard to e.g. surface area, pore
width or pore volume [59,60].
Although the high uptake efficiency of Ru@SiO2-OH
and Ru@SiO2-NH2 in our in-vitro mono-layer model
was promising, optimized conditions are needed in case
of solid HNSCC tumors where conditions of poorer vas-
cularisation may exist. Our results in HNSCC spheroids,
an established minitumor model, show that penetration
depth of Ru@SiO2-OH and Ru@SiO2-NH2 does not
reach beyond the first (outer) cell layer - independent of
nanoparticle surface charge. This observation provides
further evidence that our nanoparticles are not actively
exocytosed. Stayton et. al. showed in-vitro that nanopar-
ticles which were exocytosed in growth medium were
taken up by other cells if not removed from growth
medium [58]. Given that nanoparticles are not trans-
ported transcellularly and apparently are incapable of
passing the intercellular junction complexes, new deliv-
ery strategies have to be developed for multicellular
poorly vascularized cancers.
5. Conclusion
In summary, our study is the first to provide evidence
that core-shell silica nanoparticles may be useful tools
for the development of novel therapeutic strategies with
cancers of the head and neck region. However, before
an encapsulation of pharmaceutical compounds or a
functionalization with targeting and imaging moieties
may be considered, a better understanding of how these
nanoparticles interact with HNSCC cells on contact and
after internalization is needed. Starting from our first
steps towards clarification of endocytic pathways, further
microscopic, immunocytochemical and molecular biolo-
gical studies will elucidate nanoparticle sorting as well
as their further intracellular fate, including possible
degradation processes, or nanoparticle-mediated mole-
cular cell responses.
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